scispace - formally typeset
W

William W. Busse

Researcher at University of Wisconsin-Madison

Publications -  740
Citations -  62685

William W. Busse is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Asthma & Eosinophil. The author has an hindex of 115, co-authored 697 publications receiving 56703 citations. Previous affiliations of William W. Busse include National Institutes of Health & University at Buffalo.

Papers
More filters
Journal ArticleDOI

The effect of procaterol treatment on beta-adrenergic bronchodilation and polymorphonuclear leukocyte responsiveness.

William W. Busse, +5 more
- 01 Dec 1985 - 
TL;DR: Procaterol is a new and effective beta-adrenergic bronchodilator as mentioned in this paper, which has been shown to improve the performance of 10 patients with asthma during two 4-week double-blind treatment periods, each preceded by a 2-week beta-agonist washout.
Journal ArticleDOI

Improved exacerbation rates and asthma control in current and former smokers treated with salmeterol/fluticasone propionate: Results of the GOAL study

Homer A. Boushey, +6 more
- 01 Feb 2005 - 
Journal ArticleDOI

Possible Protective Effect of Omalizumab on Lung Function Decline in Patients Experiencing Asthma Exacerbations

William W. Busse, +6 more
- 01 Mar 2021 - 
TL;DR: Omalizumab may confer some protection against lung function decline among patients who experienced exacerbations during treatment, and in the adolescent/adult population, both exacerbators and nonexacerbators derived similar benefit with omalizuab compared with placebo.
Journal ArticleDOI

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Comparing the Efficacy and Tolerability of Levocabastine-Oxymetazoline Nasal Spray with Levocabastine and Oxymetazoline Alone in the Symptomatic Treatment of Seasonal Allergic Rhinitis

William W. Busse, +17 more
- 01 Mar 1996 - 
TL;DR: In this article, the authors evaluated the therapeutic efficacy and tolerability of twice daily administration of a nasal spray containing a combination of levocabastine and oxymetazoline (0.5 mg/mL) versus that of either agent alone in the treatment of ragweed-induced seasonal allergic rhinitis.
Proceedings ArticleDOI

Platelet Activation, P-Selectin Mobilization, And Eosinophil Beta1 Integrin Activation Occur In Asthma And Are Associated With Clinical Phenotypes

Mats W. Johansson, +6 more